Wave's stock swells as it eyes approval following Phase II DMD victory [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
Chief development officer, Anne-Marie Li-Kwai-Cheung said: “The high and consistent dystrophin levels at this interim timepoint are compelling and speak to the potential of WVE-N531 for boys amenable to exon 53 skipping, where better therapeutic options are urgently needed.” The open-label trial is investigating WVE-N531 in 11 boys, aged five to 11 with DMD who are amenable to exon 53 skipping. There was a mean absolute muscle content-adjusted dystrophin expression of 9%. The mean absolute unadjusted dystrophin expression was 5.5%, as measured by Western Blot. Dystrophin expression was quantified from two isoforms consistent with those observed in Becker muscular dystrophy patients who display milder disease. Patients also showed multiple indicators of improvement in muscle health. Mean exon skipping was 57% as measured by reverse transcription polymerase chain reaction (RT-PCR). Complete 48-week data from the FORWARD-53 trial is also expected to be announced in Q1 2025. Th
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Maxim Group from $12.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Capricor surges on plans to seek FDA approval for lead asset [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyGlobeNewswire
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.MarketBeat
CAPR
Earnings
- 8/7/24 - Miss
CAPR
Sec Filings
- 9/24/24 - Form SC
- 9/24/24 - Form 4
- 9/24/24 - Form 8-K
- CAPR's page on the SEC website